Akari Therapeutics Partners with WuXi XDC, Accelerating Novel ADC Payload IND Filing to Late 2026
Summary
Akari Therapeutics announced a strategic partnership with WuXi XDC, a global leader in ADC development, to advance its novel PH1 payload technology. This collaboration is expected to accelerate the Investigational New Drug (IND) filing for Akari's lead program, AKTX-101, to late 2026. This development provides a significant positive catalyst for Akari, especially following its recent 10-K filing which reported a substantial net loss and a 60% reduction in R&D. For a micro-cap biotech, securing a partnership with a reputable industry leader like WuXi XDC offers crucial validation for its novel RNA splicing modulating payload and significantly de-risks and accelerates its pipeline progression towards clinical trials. Investors will now closely monitor the progress towards the IND filing and the subsequent initiation of Phase 1 clinical trials for AKTX-101.
At the time of this announcement, AKTX was trading at $5.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $4.16 to $63.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.